QIAGEN announced a collaboration on a biotech deal with Eli Lilly and Company to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.
The agreement includes the development of tests that will be based on QIAGEN’s multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.
The new collaboration is the fourth project in the two companies’ long-standing partnership.
QIAGEN’s therascreen KRAS RGQ PCR Kit has been widely adopted by laboratories since its 2012 approval by the U.S. Food and Drug Administration (FDA) as a companion diagnostic to detect KRAS gene mutations in metastatic colorectal cancer patients.
The test indicates which patients would benefit from a tailored oncology therapy marketed by Lilly and Bristol-Myers Squibb.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Eli Lilly
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity